Maeda K, Usuda M, Kawaguchi S, Shinzato T, Saito A, Ohta K, Kobayashi K, Ohbayashi S, Narita M
Artif Organs. 1980 Feb;4(1):30-3. doi: 10.1111/j.1525-1594.1980.tb03897.x.
Administration of ticlopidine, a new inhibitor of platelet aggregation, during hemodialysis to two patients with thrombotic occlusion of external A-V shunts markedly suppressed the obstruction of the shunt and improved anemia. Consequently, it was concluded that this drug may be useful for maintaining good blood flow and good patency of shunts in patients undergoing dialysis. In order to determine the dialyzer efficiency during dialysis, the reduction rate of the dialyzer was determined in vitro. The dialyzer reduction rates for urea, creatinine, uric acid, and phosphoric acid were all lowered after dialysis, and the administration of ticlopidine resulted in a suppression of the drop in the reduction rate. Based on the inhibitory effect of ticlopidine on platelet aggregation, it was assumed that a close correlation may exist between adhesion and aggregation of platelets and the drop in the efficiency of the dialyzer during dialysis as well as thrombotic obstruction of shunts.
对两名患有体外动静脉分流血栓闭塞的患者在血液透析期间给予新型血小板聚集抑制剂噻氯匹定,显著抑制了分流的阻塞并改善了贫血。因此,得出结论,该药物可能有助于维持透析患者分流的良好血流和通畅性。为了确定透析期间透析器的效率,在体外测定了透析器的降低率。透析后尿素、肌酐、尿酸和磷酸的透析器降低率均降低,而噻氯匹定的给药导致降低率下降的抑制。基于噻氯匹定对血小板聚集的抑制作用,推测血小板的黏附和聚集与透析期间透析器效率的下降以及分流的血栓性阻塞之间可能存在密切相关性。